Researcher:
Sharifi, Samira

Profile Picture
ORCID

OrgUnit Logo
Organizational Unit

Job Title

Undergraduate Student

First Name

Samira

Last Name

Sharifi

Name

Name Variants

Sharifi, Samira

Email Address

Birth Date

Filters

2020 - 20212

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.7736cc2f-e022-4183-b10a-37907061aed2

Search Results

Now showing 1 - 2 of 2
  • Placeholder
    PublicationMetadata only
    A review on the effect of air pollution and exposure to PM, NO2, O3, SO2, CO and heavy metals on viral respiratory infections
    (Tehran University of Medical Sciences, 2020) Khajeamiri, Yasaman; Moradpour, Nioosha; Khajeamiri, Alireza; Sharifi, Samira; Undergraduate Student; School of Medicine; N/A
    The ambient air pollutants that have a major role in causing respiratory diseases are particulate matter, sulfur dioxide, nitrogen dioxide, ozone, carbon monoxide, and heavy metals. In addition, respiratory infections, divided into upper respiratory tract and lower respiratory tract infection, are most commonly caused by viral agents. Thus, in light of the current COVID-19 pandemic, this review has focused on the association between exposure to general air pollution including each of the mentioned air pollutants and viral respiratory infections. The gathered evidence from the reviewed studies in this article showed that most of these air pollutants have a positive correlation with mortality, severity, transmission, inflammation, and incidence of different viral respiratory infections. Whereas, some studies found contradictory results such as non-significant and negative connections between exposure to air pollutants and viral respiratory infections, which are further discussed in this text. Therefore, following the SARS-CoV-2 outbreak, these contradictions in the reported correlation between air pollution and different aspects of viral respiratory infections must be thoroughly investigated and cleared.
  • Placeholder
    PublicationMetadata only
    Hypofractionated frameless gamma knife radiosurgery for large metastatic brain tumors
    (Springer, 2021) Samancı, Mustafa Yavuz; Şişman, Uluman; Altıntaş, Alara; Sarıoğlu, Sebile; Sharifi, Samira; Atasoy, Ali İhsan; Bölükbaşı, Yasemin; Peker, Selçuk; Faculty Member; Undergraduate Student; Undergraduate Student; Undergraduate Student; Undergraduate Student; Other; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; 275252; N/A; N/A; N/A; N/A; N/A; 216814; 11480
    Hypofractionated stereotactic radiosurgery has become an alternative for metastatic brain tumors (METs). We aimed to analyze the efficacy and safety of frameless hypofractionated Gamma Knife radiosurgery (hfGKRS) in the management of unresected, large METs. All patients who were managed with hfGKRS for unresected, large METs (> 4 cm(3)) between June 2017 and June 2020 at a single center were reviewed in this retrospective study. Local control (LC), progression-free survival (PFS), overall survival (OS), and toxicities were investigated. A total of 58 patients and 76 METs with regular follow-up were analyzed. LC rate was 98.5% at six months, 96.0% at one year, and 90.6% at 2 years during a median follow-up of 12 months (range, 2-37). The log-rank test indicated no difference in the distribution of LC for any clinical or treatment variable. PFS was 86.7% at 6 months, 66.6% at 1 year, and 58.5% at 2 years. OS was 81% at 6 months, 63.6% at one year, and 50.7% at 2 years. On the log-rank test, clinical parameters such as control status of primary cancer, presence of extracranial metastases, RTOG-RPA class, GPA group, and ds-GPA group were significantly associated with PFS and OS. Patients presented with grade 1 (19.0%), grade 2 (3.5%) and grade 3 (5.2%) side effects. Radiation necrosis was not observed in any patients. Our current results suggest that frameless hfGKRS for unresected, large METs is a rational alternative in selected patients with promising results.